CureVac indicates immune response from COVID-19 vaccine candidate

by on

CureVac indicates immune response from COVID-19 vaccine candidate
tjordan_drupal
Nov 3, 2020

German biotech firm CureVac N.V. yesterday announced interim data from its ongoing Phase 1 dose-escalation study evaluating its CVnCoV SARS-CoV-2 vaccine candidate for safety, reactogenicity and immunogenicity.

CureVac said it has early indications that CVnCoV generates a balanced immune response, similar to that of natural COVID-19 infection. The drug maker said its data supports the beginning of a Phase 2b/3 clinical trial before the end of 2020 for a 12 microgram dose of the candidate.

Headline

CureVac indicates immune response from COVID-19 vaccine candidate
tjordan_drupal
Nov 3, 2020

German biotech firm CureVac N.V. yesterday announced interim data from its ongoing Phase 1 dose-escalation study evaluating its CVnCoV SARS-CoV-2 vaccine candidate for safety, reactogenicity and immunogenicity.

CureVac said it has early indications that CVnCoV generates a balanced immune response, similar to that of natural COVID-19 infection. The drug maker said its data supports the beginning of a Phase 2b/3 clinical trial before the end of 2020 for a 12 microgram dose of the candidate.

Novel Coronavirus (COVID-19)
COVID-19: Vaccine

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: